English
Japan
Piscataway, NJ May 2011 — Genscript Inc, today announced a strategic collaboration and business alliance in synthetic biology with Evozym Biologics, Inc.. The companies intend to develop next generation proteins and enzymes by combining Evozym Biologics' innovative enzyme/protein design capabilities with GenScript's gene synthesis and protein expression capabilities. "GenScript is a premier biotech company and DNA synthesis company", says Joseph Grzymski co-founder and President of Evozym. "We are incredibly excited to introduce them to our protein evolution and computational design platforms. We believe our collaboration will allow both companies to leverage strengths and create next generation bio-products efficiently and cost-effectively."
About Genscript
GenScript is the leading gene, peptide, protein and antibody research partner for fundamental life science research, translational biomedical research, and early stage pharmaceutical development. Since our establishment in 2002, GenScript has exponentially grown to become a global leading biotech company that provides life sciences services and products to scientists over 100 countries worldwide. During our tenure we have built the best-in-class capacity and capability for biological research services encompassing gene synthesis and molecular biology, peptide synthesis, custom antibodies, protein expression, antibody and protein engineering, and in vitro and in vivo pharmacology – all with the goal to Make Research Easy.
About Evozym Biologics, Inc.
Evozym Biologics, Inc., is an evolutionary and environmental biology company revolutionizing statistical genomics to exploit new potentials for bioengineered protein design, bioremediation and drug-targeting. Two professors, Joseph J. Grzymski and Adam G. Marsh, with more than 25 years research experience, founded the company. Evozym's proprietary platform technology utilizes evolutionary and environmental biology combined with multi-core computation to bioengineer the evolutionary construction of novel proteins or the deconstruction of existing proteins into their most critical functional components. The unique ability to apply a revolutionary understanding of gene and protein architecture provides a next-generation approach to a suite of genes, proteins and bioprocesses that will change the economic paradigm of discovery and production in multiple biologics-oriented market segments. www.evozym.com
# # # #
For further information, please contact:
Sally Wang
Executive Vice President
GenScript
[email protected]
1-(732) 885-9188
Source: http://www.genscript.com
Your Innovation Partner in Drug Discovery!
Have you wondered how much Tameka Cottle changed after plastic surgery? Look this cover story.
Also, read a schocking story about Tameka Cottle’s husband.
